Enterprise Value

1.958B

Cash

272.5M

Avg Qtr Burn

-37.96M

Short % of Float

12.59%

Insider Ownership

28.48%

Institutional Own.

72.00%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details
GIST (Gastrointestinal stromal tumors) (fourth-line)

Approved

Quarterly sales

Qinlock (Ripretinib) Details
Gastrointestinal stromal tumors

Phase 3

Data readout

Vimseltinib (DCC-3014) (CSF1R inhibitor) Details
Tenosynovial Giant Cell Tumors, Cancer

Phase 3

Data readout

Vimseltinib (DCC-3014) (CSF1R inhibitor) Details
Cancer, Tenosynovial Giant Cell Tumors

Phase 1/2

Data readout

Phase 1/2

Update

DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 1

Data readout

DCC-3116 (Inhibitor of ULK)+Qinlock Details
Solid tumor/s, Gastrointestinal stromal tumors

Phase 1

Data readout

Failed

Discontinued